# US 2024/0199648 A1 · Map4k1 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199648 A1
- Document ID: US20240199648A1
- Status: Published application
- Kind: A1
- Application number: 18/280,900
- Filed: 2022-03-07
- Published: 2024-06-20
- Earliest claimed: 2021-03-08
- Assignees: Blueprint Medicines Corporation
- Applicants: Blueprint Medicines Corporation
- Inventors: Jason D. Brubaker; Michael J. Burke; Joshua T. Close; Thomas A. Dineen; Chandrasekhar V. Miduturu; Emanuele Perola
- Web page: https://patentgrep.com/patent/US20240199648A1

## CPC

- C07D 498/06: Peri-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/4725: containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 491/052: the oxygen-containing ring being six-membered
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

## Claims

### Claim 1

A compound of Formula I
or a pharmaceutically acceptable salt thereof,
wherein:
T is selected from
-L1-C(O)—NR11R12, -L1-O—C(O)—NR11R12 and -L2-NR13—C(O)—R14;
Ring A is C4-6 cycloalkyl or 4-6 membered heterocycle containing nitrogen, wherein said cycloalkyl or heterocycle is optionally substituted with 1-2 R6; each R6 is independently selected from CH3, methoxy, CF3, CH2F, and CHF2;
L1 and L2 are each independently selected from C1-C3 alkylene optionally substituted with 1-2 R15;
each s is independently selected from 1, 2, and 3;
B is O or NH;
Q is N or CH;
x is 0, 1, or 2;
R1 and R2 are each independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, and 4 to 6-membered heterocycle, wherein said alkyl is optionally substituted with 1-2 R3;
each R3 is independently selected from halogen, hydroxyl and OR4; or
each R4 is independently selected from C1-3 alkyl, CF3, CH2F, and CHF2;
each R5 is independently selected from C1-2 alkyl, CF3, CH2F, and CHF2, or
two R5 attached to the same carbon atom taken together with the carbon atom to which they attach form C3-5 cycloalkyl; or two R5 attached to two adjacent carbon atoms taken together with the two adjacent carbon atoms to which they attach form C4-6 cycloalkyl;
n is 0, 1, 2, 3, or 4;
R7 is selected from C1-3 alkyl, C3-6 cycloalkyl, OC1-4 alkyl, NR9R10, and 3-5 membered heterocycle containing nitrogen or oxygen, wherein said alkyl, cycloalkyl, or heterocycle is optionally substituted with 1-3 R8;
each R8 is independently selected from halogen, C1-3 alkyl, CF3, CH2F, CHF2, hydroxyl, OC1-3 alkyl, OCF3, OCH2F, and OCHF2;
R9 is selected from C1-2 alkyl;
R10 is selected from C1-2 alkyl
R11 is selected from C1-3alkyl;
R12 is selected from C1-3 alkyl; or R11 and R12 taken together with the nitrogen atom to which they attach form 4 to 6-membered heterocycle containing nitrogen;
R13 is H or C1-2alkyl;
R14 is C1-3alkyl, or R13 and R14 taken together with the atoms to which attach form 4 to 6-membered heterocycle containing nitrogen; and
each R15 is independently selected from halogen, methoxy, and C1-2alkyl, or two R15 taken together with the two adjacent carbon atoms to which they attach form cyclopropyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
T is selected from
-L1-C(O)NR11R12, and -L2-NR13C(O)R14.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
L1 is selected from —(CH2)3— and:
L2 is —(CH2)2—;
R1 and R2 are each independently selected from hydrogen, C1-4 alkyl, C3-4 cycloalkyl, and
4 to 5-membered heterocycle, wherein said alkyl is optionally substituted with one R3; each R3 is independently selected from F, Cl, hydroxyl and OR4;
each R4 is independently selected from CH3, CH2CH3, and CF3;
each R5 is independently selected from CH3 and CF3, or
two R5 attached to the same carbon atom taken together with the carbon atom to which they attach form C3-4 cycloalkyl; or two R5 attached to two adjacent carbon atoms taken together with the two adjacent carbon atoms to which they attach form C4-5 cycloalkyl;
n is 1, 2, 3, or 4;
each R6 is independently selected from CH3, CF3, CH2F and CHF2;
R7 is selected from C1-2 alkyl, C3-5 cycloalkyl, OC1-3 alkyl, NR9R10, and 3-5 membered heterocycle containing nitrogen or oxygen, wherein said alkyl, cycloalkyl, or heterocycle is optionally substituted with 1-3 R8;
each R8 is independently selected from halogen, C1-2 alkyl, CF3, CHF2, hydroxyl, OC1-2 alkyl, OCF3, and OCHF2;
R9 is CH3;
R10 is CH3;
R11 is CH3;
R12 is CH3;
R13 is CH3; and
R14 is CH3; or R13 and R14 taken together with the atoms to which they attach form 5-membered heterocycle containing nitrogen,
wherein:
represents the point of attachment to B; and
represents the point of attachment to —C(O)NR11R12.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is represented by Formula II:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is represented by Formula III:
or a pharmaceutically acceptable salt thereof.

### Claim at position 6

-8. (canceled)

### Claim 9 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein:
Ring A is selected from cyclobutylene, azetidinylene, and pyrrolidinylene, wherein said cyclobutylene, azetidinylene, or pyrrolidinylene is optionally substituted with one R6.

### Claim 10 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein:
Ring A is C4-6 cycloalkyl optionally substituted with 1-2 R6, and R7 is NR9R10 or 3-5 membered heterocycle containing nitrogen, wherein a ring nitrogen of the 3-5 membered heterocycle is bonded to R7—C(O, and the heterocycle is optionally substituted with 1-3 R8;
Ring A is 4-6 membered heterocycle containing nitrogen, wherein a ring nitrogen of the 4-6 membered heterocycle is bonded to R7—C(O, and the heterocycle is optionally substituted with 1-2 R6.

### Claim 11 (depends on 5)

The compound of claim 5, wherein the compound is represented by Formula VII:
or a pharmaceutically acceptable salt thereof,
wherein:
W is N or CH; and
m is 0 or 1.

### Claim at position 10

-13. (canceled)

### Claim 14 (depends on 5)

The compound of claim 5, wherein the compound is represented by Formula VIII(A), VIII(B), or VIII(C):
or a pharmaceutically acceptable salt thereof, wherein:
m is 0 or 1.

### Claim at position 12

-16. (canceled)

### Claim 17 (depends on 14)

The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein:
R6 is CH3;
R1 and R2 are each independently selected from hydrogen, CH3, CH2CH3, and CH2OCH3;
each R5 is CH3 or two R5 attached to the same carbon atom taken together with the carbon atom to which they attach form a cyclopropyl:
n is 1, 2, 3, and 4; and
R7 is selected from CH3, CH2CH3, N(CH3)2, OC1-2alkyl, cyclopropyl, azetidinyl, oxetanyl, tetrahydrofuranyl, wherein R7 is optionally substituted with 1-2 R8; and
each R8 is independently selected from F, CH3, CH2CH3, OH, OCH3, and CF3.

### Claim at position 14

-20. (canceled)

### Claim 21 (depends on 17)

The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein:
when R7—C(O is bonded to a ring carbon, R7 is N(CH3)2 or azetidinyl, wherein said azetidinyl is optionally substituted with 1-2 R8;
when R7—C(O is bonded to a ring nitrogen, R7 is selected from CH3, CH2CH3, N(CH3)2, OC1-2alkyl, cyclopropyl, azetidinyl, oxetanyl, and tetrahydrofuranyl, wherein said CH3, CH2CH3, OC1-2alkyl, cyclopropyl, azetidinyl, oxetanyl or tetrahydrofuranyl is optionally substituted with 1-2 R8; and
each R8 is independently selected from F, CH3, CH2CH3, OH, OCH3, and CF3.

### Claim 22 (depends on 17)

The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein:
R7 is independently selected from CH3, CH2CH3, N(CH3)2, OCH3, OCH2CH3, CH2OCH3,
represents the point of attachment to —C(O).

### Claim 23 (depends on 22)

The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein:
when R7—C(O is bonded to a ring carbon, R7 is selected from N(CH3)2,
when R7—C(O is bonded to a ring nitrogen, R7 is selected from CH3, CH2CH3, N(CH3)2, OCH3, OCH2CH3, CH2OCH3,
represents the point of attachment to —C(O).

### Claim 24 (depends on 1)

The compound of claim 1, wherein the compound is represented by Formula XI:
or a pharmaceutically acceptable salt thereof,
wherein:
W is N or CH;
R1 and R2 are each independently selected from hydrogen, CH3, and CH2CH3;
each R5 is CH3;
n is 2 or 3;
R6 is CH3;
m is 0 or 1;
R7 is selected from CH3, CH2CH3, cyclopropyl,
and
wherein
represents the point of attachment —C(O).

### Claim 25 (depends on 24)

The compound of claim 24, or a pharmaceutically acceptable salt thereof, wherein:
when R7—C(O is bonded to a ring carbon, R7 is
when R7—C(O is bonded to a ring nitrogen, R7 is selected from CH3, CH2CH3, cyclopropyl
represents the point of attachment —C(O).

### Claim at position 20

-28. (canceled)

### Claim 29

A compound of Table 1 or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim at position 23

-32. (canceled)

### Claim 33 (depends on 1, 30)

A method for treating a MAP4K1-dependent disorder or disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; or the pharmaceutical composition of claim 30.

### Claim 34 (depends on 33)

The method of claim 33, wherein said MAP4K1-dependent disease or disorder is a cancer.

### Claim 35 (depends on 34)

The method of claim 34, wherein the cancer comprises at least one cancer selected from the group consisting of colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, bladder cancer, stomach cancer, liver cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma.

### Claim at position 27

-37. (canceled)
